[Development of a Novel Therapeutic for Pediatric Heart Failure Targeting Angiotensin II Receptor]

Area of Science:

• Cardiovascular Research
• Pediatric Pharmacology
• Drug Discovery

Background:

• Pediatric drug development faces unique challenges due to children's distinct physiological characteristics.
• Pediatric heart failure, especially in neonates, has limited therapeutic options.
• Angiotensin II signaling pathways (G protein and β-arrestin) are crucial in cardiac function.

Purpose of the Study:

• To investigate TRV027, a β-arrestin-biased AT₁R agonist, for pediatric heart failure treatment.
• To evaluate the efficacy and safety of TRV027 in neonatal cardiac models.

Main Methods:

• Utilized neonatal mouse models and human induced pluripotent stem cell-derived cardiomyocytes.
• Administered TRV027 acutely and chronically to assess cardiac function and survival rates.
• Measured inotropic effects, heart rate, oxygen consumption, and reactive oxygen species production.

Main Results:

• TRV027 demonstrated a positive inotropic effect in neonatal mouse hearts without adverse effects on heart rate or oxygen consumption.
• The drug's efficacy was confirmed in human iPS cell-derived cardiomyocytes and a neonatal mouse model of dilated cardiomyopathy.
• Chronic TRV027 administration significantly improved survival rates in preweaning mice with dilated cardiomyopathy.

Conclusions:

• TRV027 exhibits potential as a safe and effective therapeutic agent for pediatric heart failure.
• Targeting the β-arrestin pathway of AT₁R offers a promising strategy for neonatal cardiac treatment.
• Further research into TRV027 is warranted for pediatric heart failure management.